Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CALCA | P06881 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301700 | 0.88 | SIGMAR1 (0.42) | SIGMAR1HTR2CDPP4DPP7HTR2A | |
| SCHEMBL1109657 | 0.85 | SIGMAR1 (0.41) | SIGMAR1HTR2CDPP4DPP7HTR2A | |
| SCHEMBL10772014 | 0.85 | ALDH1A1 (0.50) | SIGMAR1HTR2CDPP4DPP7HTR2A | |
| Hydrochloric Acid SCHEMBL7293029 | 0.84 | SIGMAR1 (0.40) | SIGMAR1HTR2CDPP4DPP7HTR2A | |
| Hydrochloric Acid SCHEMBL28338297 | 0.81 | MAPT (0.41) | KDM4EMEN1KMT2A | |
| SCHEMBL4977025 | 0.79 | SLC18A3 (0.44) | HTR2CHTR2AHTR2BCYP2D6SLC6A2 | |
| SCHEMBL8496002 | 0.79 | DPP4 (0.45) | SIGMAR1HTR2CDPP4DPP7HTR2A | |
| SCHEMBL470870 | 0.78 | P2RX7 (0.43) | HTR2CHTR2AHTR2BCYP2D6SLC6A2 | |
| SCHEMBL3978422 | 0.78 | SLC6A2 (0.41) | SIGMAR1HTR2CHTR2AHTR2BCYP2D6 | |
| SCHEMBL410563 | 0.78 | P2RX7 (0.43) | HTR2CHTR2AHTR2BCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7834001-B2 | N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | SIGMAR1 522/4885HTR2C 3134/4885DPP4 2872/4885 |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | ATP2A1, ATP2A3, KCNN4 | SIGMAR1 522/4885HTR2C 3134/4885DPP4 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.